Larimar Therapeutics, Inc.
LRMRHeld by 5 specialist biotech funds
High Convergence5 funds opened new positions. Next phase2 readout (CTI-1601): Jan 2027. Short interest: 10.9% of float.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.